What is the Auryon Atherectomy System?
The Auryon Atherectomy System is a proprietary solid-state laser technology platform that is FDA-indicated for use in the treatment, including atherectomy, of infrainguinal stenoses and occlusions, including in stent restenosis. The Auryon System utilizes a solid state 355nm short-pulse laser that is safe and effective in the treatment for infrainguinal atherosclerosis (above and below the knee) in all lesion types and calcification levels with preserving the integrity of endothelial wall of the vessel
Auryon System Device Training
Please contact our representative to learn more.
- Herzog A, Oszkinis G, Planer D, et al. Atherectomy using a solid-state laser at 355 nm wavelength. J. Biophoton. 2017;10:1-8. https://doi. org/10.1002/jbio.201600209.
- Rundback J, et al. 6-month pivotal data from the EX-PAD-03 U.S. Investigation Device Exemption (IDE) Trial evaluating the B-Laser™ in patients with symptomatic PAD
- Shammas NW, Chandra P, Brodmann M, Weinstock B, Sedillo G, Cawich I, et al. Acute and 30-day safety and effectiveness evaluation of Eximo Medical’s B-Laser, a novel atherectomy device, in subjects affected with infrainguinal peripheral arterial disease: Results of the EX-PAD-03 trial. Cardiovasc Revasc Med 2020;21:86–92.
GENERAL NOTE: B-Laser was the initial name of the device. In 2020, the name “B-Laser” was replaced by the Auryon Atherectomy System. Both names (B-Laser and the Auryon Atherectomy System, also referred to simply as “Auryon”) refer to the same device. All references for B-Laser on this website, supporting documents including publications and on the device labeling for this study, refer to the Auryon Atherectomy System.
AngioDynamics, Auryon, and B-Laser are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary. All other trademarks are property of their respective owners.